Abbisko Cayman and Sanofi side by side
Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.
At a glance
Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.
Pipeline by phase
Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.
| Furthest phase | Abbisko Cayman | Sanofi |
|---|---|---|
| Phase 1 | 25% | Sanofi: 23 of its 81 programs at phase 1
and 18 more — sign in to see them all |
| Phase 2 | Abbisko Cayman: 5 of its 8 programs at phase 2
| Sanofi: 25 of its 81 programs at phase 2
and 20 more — sign in to see them all |
| Phase 3 | Abbisko Cayman: 1 of its 8 programs at phase 3
| Sanofi: 22 of its 81 programs at phase 3
and 17 more — sign in to see them all |
| Approved, new studies | 00% | Sanofi: 11 of its 81 programs at approved, new studies
and 6 more — sign in to see them all |
Readouts ahead
Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.
| Nov ’26 | Dec | Jan ’27 | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbisko Cayman2 readouts · 0 phase 3 | · | · | · | · | · | · | · | Abbisko Cayman, Jun ’27: 1 program whose next study reaches primary completion
| Abbisko Cayman, Jul ’27: 1 program whose next study reaches primary completion
| · | · | · |
| Sanofi30 readouts · 10 phase 3 | Sanofi, Nov ’26: 3 programs whose next study reaches primary completion, 3 in phase 3
| Sanofi, Dec ’26: 5 programs whose next study reaches primary completion, 1 in phase 3
| Sanofi, Jan ’27: 5 programs whose next study reaches primary completion, 1 in phase 3
| Sanofi, Feb ’27: 2 programs whose next study reaches primary completion, 2 in phase 3
| Sanofi, Mar ’27: 1 program whose next study reaches primary completion, 1 in phase 3
| Sanofi, Apr ’27: 6 programs whose next study reaches primary completion
and 1 more — sign in to see them all | Sanofi, May ’27: 1 program whose next study reaches primary completion
| Sanofi, Jun ’27: 2 programs whose next study reaches primary completion
| Sanofi, Jul ’27: 1 program whose next study reaches primary completion, 1 in phase 3
| Sanofi, Aug ’27: 1 program whose next study reaches primary completion
| Sanofi, Sep ’27: 2 programs whose next study reaches primary completion, 1 in phase 3
| Sanofi, Oct ’27: 1 program whose next study reaches primary completion
|
Changed in the last 90 days
Since Aug 20, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.
Abbisko Cayman
New programs 0
None
Reached a new phase 0
None
Study stopped 0
None
Primary completion later 2
- pimicotinibphase 1 · Dec 2026 → Dec 2031 (+60 mo) · moved Nov 9 · NCT04192344
- PD-L1 Inhibitor ABSK043phase 1 · Oct 2022 → Jul 2027 (+57 mo) · moved Nov 6 · NCT04964375
Sanofi
New programs 6
- SAR448632phase 1 · first study · Nov 12
- DTaP-IPV-HB-PRP~T combined vaccinephase 3 · first study · Nov 10 · Diphtheria
- Dupilumab coformulated with berahyaluronidase alfaphase 3 · first study · Oct 30 · Dermatitis, Atopic
- NVXC19phase 3 · first study · Oct 15 · Influenza, Human
- NVX-CoV2373 adjuvated lipid nanoparticleapproved, new study · first study · Sep 30 · COVID-19
- Bivalent RSV+HMPV protein vaccinephase 2 · first study · Sep 3
Reached a new phase 1
- IIV-HD + NVXC19 combinationphase 3 · Oct 15 · Influenza, Human
Study stopped 4
- balinatunfibphase 2 · terminated Oct 22 · none of its studies left running“Business decision” · NCT07222189
- balinatunfibphase 2 · terminated Oct 21 · none of its studies left running“Business decision” · NCT06867094
- balinatunfibphase 2 · terminated Oct 13 · none of its studies left running“Business decision.” · NCT06637631
- amlitelimabphase 2 · terminated Oct 2“Sponsor decision; the decision is not related to any safety concern.” · NCT06033833
Primary completion later 2
- belumosudilphase 1 · Sep 2026 → Jan 2027 (+4 mo) · moved Nov 10 · NCT07726914
- rilzabrutinibphase 2 · Aug 2026 → Feb 2027 (+6 mo) · moved Oct 1 · NCT06984627
Where they overlap
Conditions where at least two of them have programs: 1 in all. A program counts in each condition its studies name most.
| Condition | Abbisko Cayman | Sanofi |
|---|---|---|
| Carcinoma, Non-Small-Cell Lungboth · compare here | Abbisko Cayman in Carcinoma, Non-Small-Cell Lung: 2 programs
Their studies: Abbisko Cayman’s studies of Carcinoma, Non-Small-Cell Lung in search | Sanofi in Carcinoma, Non-Small-Cell Lung: 2 programs
Their studies: Sanofi’s studies of Carcinoma, Non-Small-Cell Lung in search |
Same targetBetaPro · free during the beta
Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.
| Target | Abbisko Cayman | Sanofi |
|---|---|---|
| KRAS | glecirasibrule | Pan-KRAS Inhibitor BLU-924 |
What this can't show
- Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
- Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
- Readout dates are the sponsors’ estimates, not results.
- A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
- “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
- Programs a company names but has not registered are counted apart (Sanofi: 12).